| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.21 | 5e-05 |
| mRNA | IPA-3 | GDSC1000 | pan-cancer | AAC | -0.14 | 0.0001 |
| mRNA | BRD-K33514849 | CTRPv2 | pan-cancer | AAC | 0.46 | 0.0001 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | 0.18 | 0.0002 |
| mRNA | Docetaxel | gCSI | pan-cancer | AAC | -0.2 | 0.0002 |
| mRNA | thapsigargin | gCSI | pan-cancer | AAC | -0.21 | 0.0003 |
| mRNA | paclitaxel | gCSI | pan-cancer | AAC | -0.19 | 0.0005 |
| mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.0006 |
| mRNA | AEW541 | CCLE | pan-cancer | AAC | 0.17 | 0.001 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.11 | 0.001 |